Brazil cancer drug access crisis

In late July 2026, reports highlighted extreme financial barriers for Brazilian children with serious cancers, including a 10‑year‑old needing a R$3 million bone‑marrow transplant drug and a 7‑year‑old receiving palliative care. By early August, a court in Roraima ordered the state to supply the high‑cost melanoma drug Nivolumab (≈R$16,000 per dose) after a treatment interruption caused disease progression, imposing daily fines for non‑compliance. Simultaneously, the Associação Petropolitana dos Pacientes Oncológicos (APPO) in Petrópolis sold a 2014 Fiat Siena (≈R$34,000) to fund its Casa de Apoio shelter, preserving multidisciplinary services such as nutrition, psychology, physiotherapy and social support.

The crisis deepened on 6 August when Mariana Siqueira de Souza, a resident of Marilândia do Sul, Paraná, died after courts denied her request for an estimated R$540,000 melanoma medication. Her family launched a community fundraising campaign, underscoring the broader difficulty of obtaining life‑saving, high‑cost oncology drugs in Brazil. No further related developments have been reported since early August, indicating the situation remains unchanged.

These events trace a widening national emergency in access to expensive cancer treatments and the grassroots efforts to mitigate funding shortfalls.